

DESIGNING A NATIONAL EDUCATION PROGRAM TO SUPPORT QUALITY USE OF MEDICINES IN INFLAMMATORY BOWEL DISEASE

Sheppard, J¹, Rowett, D², O'Connor, D³, Bridges, L¹, Dartnell, J¹, Pulver, L^{1,4}, Begun, J⁵, Connor, S⁶, Massuger, W⁷, Brown, S¹, Ye, J¹

¹NPS MedicineWise, ²Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, ³Monash-Cabrini Department of Musculoskeletal Health and Clinical Epidemiology, Monash University, ⁴Council of Australian Therapeutic Advisory Groups, ⁵Mater Hospital Brisbane, ⁶Liverpool Hospital, ⁷Crohn's & Colitis Australia

Background and aim

- ▶ The use of biologics in the management of inflammatory bowel disease (IBD) has increased substantially in recent years.
- ▶ A three-year national education program has been designed and implemented for clinicians and consumers.
- ▶ The program aims to achieve better patient health outcomes, support optimal use of biological and small molecule medicines and contribute to Pharmaceutical Benefits Scheme sustainability across a range of specialty areas including gastroenterology, rheumatology and dermatology.
- ▶ The Targeted Therapies Alliance was formed and comprises of a consortium of nine organisations representing specialists, pharmacists, consumers and research experts. Affiliates include Gastroenterological Society of Australia and Crohn's & Colitis Australia.


Program objectives

- ▶ Program objectives include:
 - (1) optimise first-line therapy;
 - (2) optimise first-choice of biologic;
 - (3) optimise biosimilar prescribing and dispensing;
 - (4) optimise biologic dosage; and
 - (5) optimise glucocorticoid and analgesic use.

Methods

- ▶ The program addresses Crohn disease and ulcerative colitis.
- ▶ Co-designed with gastroenterologists and people living with IBD.
- ▶ Interventions were selected based on identified barriers, enablers and behavioural drivers, informed by the Theoretical Domains Framework.
- ▶ Key outputs of the program design phase included program objectives, audiences, focus areas, high-level key messages and intervention selection (see Figure 1).

Figure 1. Stages of program design



Conclusions

- ▶ A multidisciplinary design process has been effective in developing a national education program for gastroenterologists and their patients.
- ▶ Ongoing collaboration has fostered the opportunity to share best practice, expertise and networks.

Results

- ▶ Evidence-based resources have been developed to address key messages and program objectives. These include:
 - ▶ Webinars for gastroenterologists, nurses, general practitioners and pharmacists
 - ▶ Resources to support shared-decision making with patients including a decision aid, factsheet and action plan
 - ▶ Online articles
 - ▶ IBD module for pharmacists.

- ▶ Evidence summaries, synthesising the current emerging evidence on biologics for IBD were developed.
- ▶ An educational visiting service to discuss clinical evidence updates around medicines for IBD will be available to gastroenterologists across Australia from August 2021.



Acknowledgments

This program is funded by the Australian Government Department of Health through the Value in Prescribing – bDMARDs Program Grant.

Further information

Where to access these resources: <https://www.nps.org.au/bdmards>
To book a visit, scan the QR code:



+ TARGETED THERAPIES ALLIANCE

Helping consumers and health professionals make safe and wise therapeutic decisions about biological disease-modifying antirheumatic drugs (bDMARDs) and other specialised medicines. Funded by the Australian Government Department of Health through the Value in Prescribing bDMARDs Program Grant.



In collaboration with



Presented at GESA AGW 2021 e: info@nps.org.au